Side Effects of Cancer Treatments for Cancer Therapy Evaluation Program (CTEP) Clinical Trials
Resources for Developing Informed Consent Side Effect Tables
- Side effect tables for CTEP IND agents and novel combinations are provided directly to the lead organization during protocol development.
- To create tables for commercially-available drugs or regimens that are not available here, follow the instructions for Building Tables of Possible Side Effects for Commercial Agents (Word).
- To create tables for agents that are not commercially available, follow the instructions for Building Tables of Possible Side Effects for Investigational Agents (Word).
- Refer to the CTEP Informed Consent Risk Term Library and CTCAE IC Terms (Excel) to identify the appropriate terms.
Comments and questions can be directed to NCICTEPComments@mail.nih.gov.
CTEP-Provided Tables of Side Effects
The downloadable lists of side effects on this page describe possible side effects that may be experienced by patients taking commonly used commercially-available cancer therapy drugs or multiple-drug regimens.
Please Note: These side effect tables for commercial agents are provided as a resource for research staff and consent document authors. These documents are not approved by the NCI CIRB as patient information sheets for use in conjunction with a clinical trial.
Only use these tables as Patient Educational Materials for a clinical trial if the IRB of record for the specific trial has reviewed and approved them for that purpose.
Before any materials can be used for patient education in conjunction with a clinical trial, they must be approved by the IRB of record. US sites participating in CTEP-supported clinical trial networks can find protocol-specific NCI CIRB-approved patient educational materials on the trial development resources page.
Find and Download a List of Drug Side Effects
Browse drugs alphabetically below or type CTRL+F to search the page for a specific drug name. For a regimen or combination of multiple cancer-treatment drugs, find the entry that includes ALL the drugs in the regimen.
5
- 5-Fluorouracil (Nov 2025)
- 5-Fluorouracil, Leucovorin (2025)
- 5-Fluorouracil, Mitomycin (2025)
- 5-Fluorouracil, Oxaliplatin, Docetaxel (FLOT) (2025)
- 5-Fluorouracil, Oxaliplatin, Paclitaxel (2021)
A
- Abemaciclib (Nov 2025)
- Abiraterone (Nov 2025)
- ABVD (Doxorubicin, Bleomycin, Vinblastine, Dacarbazine) (2022)
- Ado-trastuzumab (Nov 2025)
- Anastrozole (2023)
- Arsenic Trioxide (2023)
- Asparaginase Erwinia chrysanthemi (2024)
- Atezolizumab (Nov 2025)
- AVD (Doxorubicin, Vinblastine, Dacarbazine) (2022)
- Avelumab (Nov 2025)
- Axitinib (Nov 2025)
- Azacitidine (Nov 2025)
B
- BEACOPP (Bleomycin, Etoposide, Doxorubicin, Cyclophosphamide, Vincristine, Procarbazine, Prednisone) (2022)
- Belinostat (Nov 2025)
- Bendamustine (Nov 2025)
- Bevacizumab (Nov 2025)
- Bicalutamide (2023)
- Bleomycin (2024)
- Bleomycin, Etoposide, Cisplatin (2024)
- Blinatumomab (Nov 2025)
- Bortezomib (Nov 2025)
- Brentuximab vedotin (Nov 2025)
- Brigatinib (Nov 2025)
- Busulfan (2023)
C
- Cabazitaxel (2022)
- Cabazitaxel, Prednisone (2022)
- Calaspargase (see Pegaspargase)
- Capecitabine (2023)
- Carboplatin (2024)
- Carboplatin, Cyclophosphamide, Vincristine (Apr 4, 2025)
- Carboplatin, Etoposide (Apr 2, 2025)
- Carboplatin, Etoposide, Ifosfamide (Apr 2, 2025)
- Carboplatin, Etoposide, Melphalan (Apr 2, 2025)
- Carboplatin, Etoposide, Vincristine (Apr 2, 2025)
- Carboplatin, Paclitaxel (2024)
- Carboplatin, Pemetrexed (Feb 13, 2025)
- Carboplatin, Vincristine (Feb 13, 2025)
- Carfilzomib (2023)
- Cetuximab (2023)
- CHOP (Cyclophosphamide, Doxorubicin, Vincristine, Prednisone) (2022)
- Cisplatin (Jan 13, 2025)
- Cisplatin, 5-Fluorouracil (Jan 13, 2025)
- Cisplatin, Cyclophosphamide, Etoposide, Methotrexate, Vincristine (2021)
- Cisplatin, Doxorubicin, Methotrexate (2021)
- Cisplatin, Etoposide (Jan 13, 2025)
- Cisplatin, Etoposide, Cyclophosphamide, Vincristine (Apr 4, 2025)
- Cisplatin, Gemcitabine (2022)
- Cisplatin, Vinorelbine (Jan 16, 2025)
- Cladribine (2023)
- Clofarabine (2023)
- Cyclophosphamide (2024)
- Cyclophosphamide, Carboplatin, Etoposide (Jan 1, 2025)
- Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin, Pegaspargase or Calaspargase, Thioguanine, Vincristine (2024)
- Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin, Pegaspargase or Calaspargase, Thioguanine, Vincristine, Nelarabine (2024)
- Cyclophosphamide, Cytarabine IV or SQ, Mercaptopurine (MP), Vincristine, and Pegaspargase or Calaspargase (2024)
- Cyclophosphamide, Cytarabine IV or SQ; Mercaptopurine (MP), Vincristine, and Pegaspargase or Calaspargase, Nelarabine (2024)
- Cyclophosphamide, Docetaxel (2022)
- Cyclophosphamide, Doxorubicin, Paclitaxel (Jan 25, 2025)
- Cyclophosphamide, Doxorubicin, Vincristine (2022)
- Cyclophosphamide, Topotecan (2024)
- Cyclophosphamide, Vinorelbine (Jan 29, 2025)
- Cytarabine (2022)
- Cytarabine (IT Ara-C) (2022)
D
- Dacarbazine (Nov 2025)
- Dactinomycin (2022)
- Dactinomycin, Doxorubicin, Vincristine (2022)
- Dactinomycin, Vincristine (2022)
- Darolutamide (Nov 2025)
- Dasatinib (Nov 2025)
- Daunorubicin (2022)
- Daunorubicin, Cytarabine Liposome (CPX-351) see "Vyxeos"
- Daunorubicin, Pegaspargase or Calaspargase, Dexamethasone, Vincristine (2024)
- Daunorubicin, Pegaspargase or Calaspargase, Prednisone, Vincristine (2024)
- Dexamethasone (Nov 2025)
- Dexrazoxane (2024)
- Docetaxel (Nov 2025)
- Docetaxel, Irinotecan (2022)
- Docetaxel, Prednisone (2022)
- Doxorubicin (Nov 2025)
- Doxorubicin, Ifosfamide (2022)
- Durvalumab (Nov 2025)
E
- Eflornithine (DMFA) (Nov 2025)
- Enasidenib mesylate (Nov 2025)
- Enfortumab vedotin (Nov 2025)
- Ensartinib (Nov 2025)
- Epirubicin (2024)
- EPOCH (Etoposide, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin) (2022)
- Erdafitinib (Nov 2025)
- Eribulin mesylate (Nov 2025)
- Erlotinib (Nov 2025)
- Erlotinib, Gemcitabine (2022)
- Etoposide (2024)
- Etoposide, Ifosfamide (Feb 3, 2025)
- Everolimus (2024)
- Exemestane (2023)
F
- Filgrastim (2023)
- Fludarabine (2022)
- Fludarabine, Cytarabine (2022)
- Flutamide (Nov 2025)
- FOLFIRI (Leucovorin, 5-Fluorouracil, Irinotecan) (2025)
- FOLFIRINOX (Leucovorin, 5-Fluorouracil, Irinotecan, Oxaliplatin) (2025)
- FOLFOX (Leucovorin, 5-Fluorouracil, Oxaliplatin) (2025)
- Fruquintinib (Nov 2025)
- Fulvestrant (2023)
G
- Gemcitabine (2023)
- Gemcitabine, Paclitaxel Protein-Bound Particles (2023)
- Gemtuzumab ozogamicin (Nov 2025)
- Gilteritinib (Nov 2025)
- Goserelin (Nov 2025)
H
- Herceptin Hylecta (Trastuzumab and hyaluronidase-oysk) (Nov 2025)
- Hydroxyurea (2023)
I
- Ibritumomab (2023)
- Ibrutinib (Nov 2025)
- Idarubicin (2023)
- Ifosfamide (Nov 2025)
- Imatinib (Nov 2025)
- Inotuzumab ozogamicin (Nov 2025)
- Inqovi (Nov 2025)
- Ipilimimab (Nov 2025)
- Irinotecan (2024)
- Irinotecan, Temozolomide (2024)
- Isotretinoin (2023)
L
- Larotrectinib (Nov 2025)
- Lenalidomide (Nov 2025)
- Letrozole (2023)
- Leucovorin (2023)
- Leuprolide (2022)
- Liposomal doxorubicin (2022)
- Lomustine (2024)
- Lonsurf (Trifluridine and Tipiracil) (Nov 2025)
- Lorlatinib (Nov 2025)
- Lutetium Lu 177 dotatate (Nov 2025)
M
- Melphalan (Nov 2025)
- Mercaptopurine (2023)
- Mercaptopurine PO, Methotrexate PO, Dexamethasone, Vincristine (2023)
- Mercaptopurine PO, Methotrexate PO, Dexamethasone, Vincristine, Nelarabine (2023)
- Mercaptopurine PO, Methotrexate PO, Prednisone, Vincristine (2022)
- Mesna (2022)
- Methotrexate (ITMTX) (2022)
- Methotrexate (not ITMTX) (Nov 2025)
- Methotrexate, Vinblastine, Doxorubicin, Cisplatin (2021)
- Methylprednisolone (Nov 2025)
- Mitotane (2023)
- Mitoxantrone (2023)
- Mosunetuzumab (Nov 2025)
N
- Nelarabine (Nov 2025)
- Neratinib (Dec 2025)
- Nilotinib (2024)
- Nilutamide (2023)
- Niraparib (Dec 2025)
- Nivolumab (Dec 2025)
O
- Octreotide (2023)
- Olaparib (Dec 2025)
- Opdualag (Nivolumab and Relatlimab) (Dec 2025)
- Osimertinib (Dec 2025)
- Oxaliplatin (2024)
P
- Paclitaxel (2024)
- Paclitaxel protein-bound particles (same as Nab-paclitaxel) (2023)
- Panitumumab (2024)
- Pazopanib (Dec 2025)
- Pegaspargase or Calaspargase (2024)
- Pegaspargase or Calaspargase, Vincristine (2024)
- Pegaspargase or Calaspargase, Vincristine, Methotrexate IV (2024)
- Pegfilgrastim (2023)
- Pembrolizumab (Dec 2025)
- Pemetrexed (2024)
- Pentostatin (2024)
- Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) (Dec 2025)
- Pomalidomide (Dec 2025)
- Ponatinib (2024)
- Prednisone (2022)
- Procarbazine (2022)
R
- Radium-223 dichloride (Dec 2025)
- Ramucirumab (Dec 2025)
- Regorafenib (Dec 2025)
- Rituximab (2023)
- Rucaparib (Dec 2025)
S
- Sacituzumab govitecan (Dec 2025)
- Sargramostim (Dec 2025)
- Selinexor (Dec 2025)
- Selpercatinib (Dec 2025)
- Sotorasib (Dec 2025)
- Sunitinib malate (Dec 2025)
T
- Talazoparib (Dec 2025)
- Tamoxifen (2023)
- Tazemetostat (Dec 2025)
- Teclistamab (Dec 2025)
- Temozolomide (2023)
- Thioguanine (Dec 2025)
- Thiotepa (2023)
- Tocilizumab (Dec 2025)
- Topotecan (2024)
- Tovorafenib (Dec 2025)
- Trabectedin (Dec 2025)
- Trametinib (Dec 2025)
- Trastuzumab (2024)
- Trastuzumab deruxtecan (Dec 2025)
- Tremelimumab (Dec 2025)
- Tretinoin (2023)
- Triple Intrathecals (Methotrexate, Cytarabine, Hydrocortisone) (2020)
- Triptorelin (2023)
- T-VEC (Talimogene laherparepvec) (Dec 2025)
V
- VAC (Vincristine, Dactinomycin, Cyclophosphamide) (2022)
- Vandetanib (2024)
- Vemurafenib (Nov 2025)
- Venetoclax (Nov 2025)
- Velcade, Revlimid, Dexamethasone (2022)
- Vinblastine (2024)
- Vincristine (2024)
- Vincristine, cyclophosphamide (2024)
- Vincristine, Irinotecan (2022)
- Vincristine, Pegaspargase or Calaspargase, Prednisone (2024)
- Vinorelbine (2024)
- Vismodegib (Dec 2025)
- Vorinostat (Dec 2025)
- Vyxeos (Daunorubicin and Cytarabine Liposome) (2023)